ACLARIS THERAPEUTICS INC

ACTIVE

A\239, First Floor, Okhla Industrial Area Phase \1, 宾夕法尼亚州切斯特县, Pennsylvania, Indiawww.aclaristx.comPublic101–250 employeesEstablished: 2009-01-01$84.9M

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2009

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

66.7%

Phase 3

16.7%

Phase 1

11.1%

Phase 4

5.6%

Trial Status Distribution

Active, not recruiting

8.3%

Completed

77.8%

Recruiting

2.8%

Terminated

11.1%

Clinical Trials

Trials sponsored by this organization (36)

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Phase 2

Recruiting

interventional

May 202596 participants

Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

interventional

Aug 202414 participants

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients with Moderate-to-Severe Active Psoriatic Arthritis

Phase 1

Active, not recruiting

interventional

Aug 202270 participants

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Phase 2

Terminated

interventional

Jul 202247 participants

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Phase 2

Completed

interventional

May 2022250 participants

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA) who have had an Inadequate Response to MTX Alone

Phase 1

Active, not recruiting

interventional

Mar 2022240 participants

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA) who have had an Inadequate Response to MTX Alone

Phase 1

Active, not recruiting

interventional

Feb 2022240 participants

ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA

Phase 2

Completed

interventional

Feb 2022251 participants

Page 1 of 5

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

Global Clinical Trials Landscape for Alopecia Universalis Reveals Growing Research Activity Across Major Pharmaceutical Companies

- A comprehensive 2025 clinical trials review reveals the current global research landscape for alopecia universalis, analyzing trial distribution across regions, phases, and sponsor types. - Major pharmaceutical companies including Pfizer, Johnson & Johnson, Roche, and Aclaris Therapeutics are actively participating in alopecia universalis therapeutic development programs. - The report provides critical insights into trial enrollment trends over the past five years and identifies prominent drugs currently in development for this severe autoimmune hair loss condition. - Clinical trial data is compiled from over 80 different registries worldwide, offering stakeholders comprehensive market intelligence for strategic decision-making in dermatology therapeutics.

Jul 23, 2025

Back to Organizations